Relay Therapeutics, Inc. (RLAY)
| Previous Close | 5.90 |
| Open | 5.87 |
| Bid | 5.90 x 600 |
| Ask | 5.96 x 600 |
| Day's Range | 5.71 - 5.93 |
| 52 Week Range | 5.71 - 13.32 |
| Volume | |
| Avg. Volume | 1,191,582 |
| Market Cap | 777.891M |
| Beta (5Y Monthly) | 1.63 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.79 |
| Earnings Date | May 02, 2024 - May 06, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 23.05 |
GlobeNewswireRelay Therapeutics to Participate in Upcoming Investor Conferences
CAMBRIDGE, Mass., April 11, 2024 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today announced that management will participate in three upcoming fireside chats: Stifel 2024 Virtual Targeted Oncology Forum on Wednesday, April 17, 2024 at 1:00 p.m. ETThe Citizens JMP Life Sciences Conference on Tuesday, May 14, 2024 at 11:30 a.m.
Insider Monkey11 Oversold Biotech Stocks To Buy Right Now
In this article, we will be taking a look at 11 oversold biotech stocks to buy right now. To skip our detailed analysis of the biotech sector, you can go directly to see the 5 Oversold Biotech Stocks To Buy Right Now. Dealmaking in Biotech Healthcare has been performing well so far in 2024, and […]
ZacksDoes Relay Therapeutics, Inc. (RLAY) Have the Potential to Rally 146.52% as Wall Street Analysts Expect?
The mean of analysts' price targets for Relay Therapeutics, Inc. (RLAY) points to a 146.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
